Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued Territory
📉 Boston Scientific stock has slumped roughly 55% over the last 12 months due to investor focus on weakness in electrophysiology and WATCHMAN.
💰 These challenged segments represent only 26% of the company's projected 2025 sales, leaving the majority of revenue unaffected.
📈 In Q2 2026, 74% of Boston Scientific's business achieved robust growth of 7%, indicating underlying strength despite segment-specific issues.
📉 Management has cut guidance three times, lowering organic growth forecasts to 5-6% and reducing EPS guidance to $3.28-$3.32.
🔮 The author expects Boston Scientific to return to 5-7% growth with improved 2027 EPS guidance, suggesting a potential stock repricing opportunity.
Bullish Signals
- Despite challenges in specific segments, 74% of Boston Scientific's business grew at a robust 7% in Q2 2026, indicating strong underlying operational strength.
- The challenged electrophysiology and WATCHMAN segments comprise only 26% of 2025 sales, meaning the majority of the company is not impacted by current weakness.
Risk Factors
- Boston Scientific stock has declined substantially over the recent 12-month period, recording a roughly 55% slump driven by investor pessimism.
- Management cut guidance three times, lowering organic growth expectations to 5-6% and trimming EPS guidance to $3.28-$3.32 due to weakness in electrophysiology and WATCHMAN.
Full Analysis
Boston Scientific (BSX) shares have experienced a significant decline of approximately 55% over the past 12 months, driven largely by investor concerns regarding weakness in its electrophysiology and WATCHMAN segments. Despite these specific headwinds affecting only about 26% of the company's projected 2025 sales, the broader business has demonstrated underlying resilience.
In the second quarter of 2026, 74% of Boston Scientific's total business grew at a robust rate of 7%, suggesting that the negative sentiment is not reflective of the entire portfolio. This divergence between segment-specific struggles and overall operational growth highlights a potential disconnect in current market valuations.
Management has responded to these challenges by cutting guidance three times, lowering organic growth expectations to a range of 5-6% and trimming EPS guidance to $3.28-$3.32. The author argues that this pessimism may be excessive given the strong performance of the majority of the business, anticipating a return to 5-7% growth and improved 2027 EPS guidance that could trigger a stock repricing.